The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children Source: Eur Respir J 2002; 20: 104-107 Year: 2002
Bronchodilator therapies for severe asthma Source: Eur Respir Mon 2011; 51: 253-267 Year: 2011
The effect of inhaled corticosteroids in combination with long-acting beta2-agonists in elite athletes with asthma Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Source: Eur Respir J 2001; 17: 374-379 Year: 2001
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma Source: Eur Respir J 2009; 33: 1277-1286 Year: 2009
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Source: Eur Respir J 2001; 17: 368-373 Year: 2001
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015
Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009
The effects of addition montelukast to inhaled steroids in the regular treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Comparison of long acting β 2 -agonist inhalers for treatment of exercise-induced bronchoconstriction (EIB) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012
The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Bronchodilator tolerance: the impact of increasing bronchoconstriction Source: Eur Respir J 2003; 21: 810-815 Year: 2003